<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Complete regression of primary melanoma associated with nevi involution under BRAF inhibitors: A case report and review of the literature.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Complete regression of primary melanoma associated with nevi involution under BRAF inhibitors: A case report and review of the literature." class="clickable-image" src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444337/bin/ol-17-05-4176-g02.jpg"/> </div> <div class="text-side"> <h1>Complete regression of primary melanoma associated with nevi involution under BRAF inhibitors: A case report and review of the literature.</h1> <p>Clinical, dermoscopic and pathological presentation of the second melanoma under BRAF therapy. (A) Clinical presentation showing an atypical pigmented lesion at the base of a nonpigmented papillomatous nevus. (B) Polarized dermoscopy of the new melanoma showing flat eccentric pigmentation at the base of a nonpigmented papillomatous nevus. (C) Histologic presentation of the new melanoma showing nests of melanocites with variable size and shape, pagetoid spreading, large cells with abundant eosinophilic cytoplasm with prominent nuclei. Hematoxylin and eosin; magnification, Ã—100.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/30944613/" target="_blank">30944613</a></p><p>Type: Premalignant/Malignant, Category: Melanocytic</p>
</div> </div></div></body></html>